Home > Journals > Minerva Pediatrics > Past Issues > Articles online first > Minerva Pediatrics 2021 Apr 02

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Pediatrics 2021 Apr 02

DOI: 10.23736/S2724-5276.21.05879-1

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Does levetiracetam use affect Visual Evoked Potentials (VEP) in the treatment of childhood epilepsy?

Hilal AYDIN 1 , Ibrahim H. BUCAK 2, Erman ALTUNISIK 3

1 Department of Pediatrics, Faculty of Medicine, Balikesir University, Balikesir, Turkey; 2 Department of Pediatrics, Faculty of Medicine,Adiyaman University, Adiyaman, Turkey; 3 Department of Neurology, Faculty of Medicine, Adiyaman University, Adiyaman, Turkey


PDF


BACKGROUND: Side effects of antiepileptic drugs vary depending on the drug itself, drug dose and duration of use. One of these side effects is related to vision.
METHODS: Patients who had been ordered visual evoked potential (VEP) measurements for various reasons between the dates of 01.10.2017 and 01.10.2019 at a pediatric neurology outpatient clinic and who were on levetiracetam monotherapy for at least six months for the treatment of focal/generalized epilepsy were included in the study and their files were scanned retrospectively (Study Group: SG). Patient files were evaluated for age, gender, dose and duration of levetiracetam use, presence of a family history of epilepsy, EEG result, cranial magnetic resonance imaging and VEP test results and the parameters were recorded. Twenty-four patients of similar age range without epilepsy were included in the study as the control group (CG).
RESULTS: Eighteen patients 8 boys (44.4%), 10 girls (54.6%) and 24 healthy controls 9 boys (37.5%), 15 girls (62.5%) were included in the study and control groups, respectively. No statistically significant difference was found when the mean VEP latencies were compared between the patient and control groups for the right (p: 0.451) and left (p: 0.323) eyes. There was a statistically significant difference between the groups, respectively, when VEP amplitudes of the right and left eyes of the SG and CG were compared (p: 0.001; p: 0.001). There is no correlation between levetiracetam dose and duration of treatment and VEP parameters.
CONCLUSIONS: The data obtained in this study showed that levetiracetam use affected VEP amplitude outcome but did not affect VEP latency outcome in pediatric patients.


KEY WORDS: Levetiracetam; Epilepsy; Visual evoked potential; Ocular effect

top of page